Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 10;2(2):e2010011.
doi: 10.4084/MJHID.2010.011.

Application of new drugs in chronic lymphocytic leukemia

Tadeusz Robak  1
Affiliations

Application of new drugs in chronic lymphocytic leukemia

Tadeusz Robak. Mediterr J Hematol Infect Dis. .

Abstract

Over the last few years, several new agents have been under evaluation in preclinical studies as well as in early clinical trials, and have shown promise in treating CLL. These treatments include new monoclonal antibodies (mAbs), immunomodulating agents, novel purine nucleoside analogs, Bcl-2 inhibitors and other agents. The most promising are a new mAbs targeted CD20 molecule or CD23, anti-CD40 mAbs and anti-CD37 antibody. Oblimersen, flavopiridol, and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials. However, available therapies are only partially efficient and there is an obvious need to develop better strategies and new, more specific and active drugs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Chemical structures of new drugs, potentially useful for chronic lymphocytic leukemia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Bacterial Toxins for Cancer Therapy.
    Zahaf NI, Schmidt G. Zahaf NI, et al. Toxins (Basel). 2017 Jul 28;9(8):236. doi: 10.3390/toxins9080236. Toxins (Basel). 2017. PMID: 28788054 Free PMC article. Review.

References

    1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017–29. - PubMed
    1. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs. 2009;69(17):2415–49. - PubMed
    1. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–91. - PubMed
    1. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 2007;25:793–8. - PubMed
    1. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–9. - PubMed